Encounters for infertility care are opportunities to assess and update immunization status. Women of reproductive age often are unaware of their need for immunization, their own immunization status, and the potentially serious consequences of preventable disease on pregnancy outcome. The purpose of this ASRM Practice Committee document is to summarize current recommendations regarding vaccinations for women of reproductive age. This document replaces the ASRM Practice Committee document titled, “Vaccination guidelines for female infertility patients,” last published in 2013 (Fertil Steril 2013;99:337–9). (Fertil Steril® 2018;110:838–41. ©2018 by American Society for Reproductive Medicine.)

Earn online CME credit related to this document at www.asrm.org/elearn

Discuss: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/users/16110-fertility-and-sterility/posts/34944-26574

**VACCINATION BEFORE INFERTILITY TREATMENT AND DURING PREGNANCY**

Ideally, immunizations should be completed before conception because some recommended vaccinations cannot be administered during pregnancy (1–5). Vaccinations before or during pregnancy protect women from potentially serious illnesses, prevent vertical transmission to the fetus, and confer passive immunity to the newborn. Transport of maternal immunoglobulin (IgG) antibodies to the fetus occurs throughout gestation and increases markedly during the last 4 to 6 weeks of gestation (3–5).

Many physicians are reluctant to immunize pregnant women because of concerns that an incidental congenital anomaly or spontaneous abortion might be attributed wrongly to a vaccination. This fear persists despite the fact that there are few vaccines that are contraindicated during pregnancy (2). The contraindicated vaccines include measles, mumps, and rubella (MMR); varicella; and herpes zoster. All others are either fully recommended or recommended if some other risk factor is present. Vaccinations during pregnancy are indicated when benefits clearly outweigh risks.

Special circumstances that may influence the indication for vaccination include military service, travel to high prevalence areas, hazardous occupations, immunocompromised patients, and chronic illness. Guidelines for vaccinations in individuals with such special indications are outlined in a committee opinion published by the CDC (2).

Immunizations generally recommended for women of reproductive age are listed in Table 1, which provides a condensed summary of the Recommended Adult Immunization Schedule published by the CDC. Physicians are encouraged strongly to assess the history of immunizations in women before beginning treatment for infertility.
outbreaks, health-care providers should vaccinate women contemplation are increased and lung capacity is decreased during trimester or late second trimester (i.e., after 20 weeks’ gestation). If not given during pregnancy, it should be administered immediately postpartum to ensure pertussis immunity and to reduce transmission to the newborn.

Varicella

Varicella vaccine contains live attenuated virus. Prior to pregnancy, all adults without evidence of immunity should receive 2 doses of single-antigen varicella vaccine administered 1 month apart or a second dose if they have previously received only 1 dose. Pregnancy should be avoided for 1 month after vaccination. If exposed to varicella prior to pregnancy, the vaccine should be administered within 96 hours of exposure and pregnancy avoided. Pregnant women should be assessed for evidence of varicella immunity. Pregnant women who do not show signs of immunity should receive the first dose of varicella vaccine upon completion or termination of pregnancy and before discharge from the hospital. Cases of congenital varicella after immunization have been reported.

Human Papillomavirus (HPV)

Women through age 26 and men through age 21 should be vaccinated to prevent HPV infections and HPV-associated diseases, including cancers; the dosing schedule varies based on the age that vaccination started (2). Originally, the HPV vaccine was a bivalent compound; however, the current vaccine is either quadrivalent or 9-valent (9v). Individuals who began with bivalent or quadrivalent compounds may complete the series with the 9v HPV compound. There is no ACIP recommendation regarding additional vaccination with 9v HPV for those individuals who completed

TABLE 1

Summary of the recommended adult immunization schedule outline by the Centers for Disease Control and Prevention (2).

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Age group (y)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>19–21</td>
</tr>
<tr>
<td>Influenzaa</td>
<td>1 dose annuallyb</td>
</tr>
<tr>
<td>Tetanus, diphtheria, pertussis (Td/)Tdap</td>
<td>Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yearsb</td>
</tr>
<tr>
<td>Varicela</td>
<td>2 dosesb</td>
</tr>
<tr>
<td>Human papilloma virus (HPV)a</td>
<td>3 dosesb</td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)c</td>
<td>1 or 2 dosesc</td>
</tr>
<tr>
<td>Pneumococcal (polysaccharide)</td>
<td>1 or 2 dosesc</td>
</tr>
<tr>
<td>Meningococcal</td>
<td>1 or more dosesf</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>2–3 doses depending on vaccinef</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>3 dosesf</td>
</tr>
</tbody>
</table>

a Covered by the Vaccine Injury Compensation Program.  
b For all persons in this category who meet the age requirements and who lack documentation of vaccination or have no evidence of previous infection.  
c Recommended if some other risk factor is present (e.g., based on medical, occupational, lifestyle, or other indications).  
d Tdap recommended for ≥65 if contact with <12-month-old child. Either Td or Tdap can be used if no infant contact  
e For nonpregnant women.  
f Covered by the Vaccine Injury Compensation Program.
immunization with bivalent or quadrivalent vaccines. While HPV vaccination is not recommended during pregnancy, there is no evidence that the vaccine is harmful, and no intervention is needed for women who inadvertently receive it while pregnant. Women who discover they are pregnant should delay remaining doses until after pregnancy. Pregnancy testing is not needed before vaccination [8].

**Measles, Mumps, and Rubella (MMR)**

MMR vaccine is recommended for all women without confirmed immunity to rubella. MMR vaccine contains live attenuated virus. Vaccination therefore should be administered before pregnancy to avoid the possibility of intrauterine infection, and pregnancy should be avoided for 1 month after vaccination. However, there is no confirmed instance where MMR vaccine has been linked to congenital malformation or significant intrauterine infection [9]. Consequently, inadvertent MMR administration during pregnancy is not an indication for pregnancy termination.

**NON-ROUTINE VACCINATIONS**

**Pneumococcus**

The pneumococcal vaccine is recommended for any person at increased risk for pneumococcal infection. Individuals at high risk include those with asplenia, sickle-cell anemia, chronic cardiovascular/pulmonary disease, diabetes, or immunocompromise as may result from human immunodeficiency virus (HIV) infection, systemic illness, or malignancy. Ideally, high-risk women should be immunized before pregnancy.

**Hepatitis A (HA)**

HA vaccine is recommended for any women at high risk, including those receiving clotting-factor concentrates, those with chronic liver disease, women working with HA virus or HA-infected laboratory animals, women traveling to countries with a high prevalence of HA infection, and intravenous drug users. The vaccine contains inactivated virus and poses no known risk to the fetus.

**Hepatitis B (HB)**

HB vaccine is approved for any woman at high risk, including those receiving hemodialysis or clotting-factor concentrates, health-care workers exposed to blood and blood products, intravenous drug users, women having a sexually transmitted infection or multiple sexual partners, those traveling to countries with a high prevalence of hepatitis B infection, and women living in the same household with a known infected individual. The vaccine contains noninfectious DNA particles, can be administered during pregnancy if needed, and poses no known risk to the fetus.

**Meningococcus**

The meningococcal vaccine should be administered to any person who is at increased risk for meningococcal infection. For pregnant women, its use should be limited to those at high risk who have not been inoculated previously. Individuals at high risk include those who live in high endemic areas, such as sub-Saharan Africa, parts of the Middle East, and college dormitories. Preferably, such high-risk women should be vaccinated before pregnancy, because experience with the vaccine in pregnancy is limited.

**SUMMARY**

- Vaccination in women of reproductive age before or during pregnancy confers resistance to intrauterine infections and provides the newborn with passive immunity to neonatal infections.
- Immunization schedules are best completed before beginning treatment for infertility, because some vaccinations should not be administered during pregnancy.
- Rubella and varicella immunity should be documented prior to pregnancy. If nonimmune, the vaccine should be administered and pregnancy should be avoided for 4 weeks.
- The influenza and Td immunizations should be completed before pregnancy but can be administered during pregnancy. The inactivated influenza vaccine can be given anytime during pregnancy. Tdap should be given preferably during the third trimester or late second trimester.
- Varicella, pneumococcal, HPV, HA, HB, and meningococcal vaccinations are indicated in specific circumstances and are always administered best before pregnancy.

**CONCLUSIONS**

- Prior to, during, or after pregnancy, it is important to be aware of a patient’s immunization history and to update her vaccine status when appropriate.

**Acknowledgments:** This report was developed under the direction of the Practice Committee of the American Society for Reproductive Medicine as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. The Practice Committee and the Board of Directors of the American Society for Reproductive Medicine have approved this report.

The following members of the ASRM Practice Committee participated in the development of this document. All Committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. Members of the Committee who were found to have conflicts of interest based on the relationships disclosed did not participate in the discussion or development of this document.

Alan Penzias, MD; Kristin Bendikson, MD; Samantha Butts, MD, MSCE; Tommaso Falcone, MD; Susan Gitlin,
REFERENCES


